Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.580 +0.620 (+31.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
US Stocks Mixed; Producer Prices Unchanged For November
U.S. stocks traded mixed this morning, following the release of PPI data on Wednesday. Following the market opening Wednesday, the Dow traded down 0.05% to 36,561.18 while the NASDAQ rose 0.42% to... 
Via Benzinga
Topics Stocks
C4 Therapeutics Stock Is Surging Wednesday: What's Going On?
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading higher Wednesday after the company presented data from a Phase 1 trial for the p 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. ReShape... 
Via Benzinga
Expert Ratings for C4 Therapeutics
 
Via Benzinga
D.R. Horton To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching! 
Via InvestorPlace
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Down 4%; Aditxt Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday. The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&P... 
Via Benzinga
Topics Stocks
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Jumps Over 100 Points; Oracle Posts Mixed Q2 Results
U.S. stocks turned higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.35% to 36,533.63 while the NASDAQ rose 0.16% to 14,455.15 The S&P... 
Via Benzinga
Topics Stocks
Why Is Aditxt (ADTX) Stock Up 58% Today?
Aditxt stock is up on Tuesday as investors in ADTX shares react to the company announcing plans to acquire Evofem Biosciences. 
Via InvestorPlace
EGLE Stock Pops as Star Bulk Buys Eagle Bulk for $500 Million
Eagle Bulk Shipping stock is climbing higher on Tuesday after EGLE investors learned of a merger agreement with Star Bulk Carriers. 
Via InvestorPlace
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck. 
Via InvestorPlace
US Stocks Edge Lower; Inflation Rate Slows to 3.1% In November
U.S. stocks traded slightly lower this morning, following the release of inflation data on Tuesday. Following the market opening Tuesday, the Dow traded down 0.04% to 36,389.01 while the NASDAQ fell... 
Via Benzinga
Topics Economy Stocks
Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today?
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
From C4 Therapeutics, Inc.
Via GlobeNewswire
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. 
Via Benzinga
C4 Therapeutics Announces Chief Financial Officer Succession
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.